Johnson & Johnson (JNJ) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Alphabet shares drop ahead of earnings next week
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
January 25, 2022 6:25 AM ESTNEW BRUNSWICK, N.J., Jan. 25, 2022 /PRNewswire/ --Â Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers" said Joaquin Duato, Chief Executive Officer. "Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond."
... More


